JP2013542264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542264A5 JP2013542264A5 JP2013538939A JP2013538939A JP2013542264A5 JP 2013542264 A5 JP2013542264 A5 JP 2013542264A5 JP 2013538939 A JP2013538939 A JP 2013538939A JP 2013538939 A JP2013538939 A JP 2013538939A JP 2013542264 A5 JP2013542264 A5 JP 2013542264A5
- Authority
- JP
- Japan
- Prior art keywords
- chemotherapeutic agent
- inhibition
- pharmaceutically acceptable
- acceptable salt
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 13
- 229940127089 cytotoxic agent Drugs 0.000 claims 13
- 230000005764 inhibitory process Effects 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 7
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 6
- 229960000397 bevacizumab Drugs 0.000 claims 6
- 229960004562 carboplatin Drugs 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 230000000970 DNA cross-linking effect Effects 0.000 claims 2
- 230000002112 DNA intercalation Effects 0.000 claims 2
- 230000006820 DNA synthesis Effects 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 102000029749 Microtubule Human genes 0.000 claims 2
- 108091022875 Microtubule Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 101710183280 Topoisomerase Proteins 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- -1 bevacizumab Chemical compound 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 102000006815 folate receptor Human genes 0.000 claims 2
- 108020005243 folate receptor Proteins 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 210000004688 microtubule Anatomy 0.000 claims 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 0 CC(C)=CCCNc(cc1)ccc1C(NC(CCC(NCC(NC(CCCNC(N)=N)C(NCC(N[C@@](CC(O)=O)C(NC(*)CSSCCOC(NNC([C@]1(C(*)C2C=CCN(CC3)C2C32c(cc(C)c(OC)c3)c3N(C)C12)O)=O)=O)=O)=O)=O)=O)=O)C=O)=O Chemical compound CC(C)=CCCNc(cc1)ccc1C(NC(CCC(NCC(NC(CCCNC(N)=N)C(NCC(N[C@@](CC(O)=O)C(NC(*)CSSCCOC(NNC([C@]1(C(*)C2C=CCN(CC3)C2C32c(cc(C)c(OC)c3)c3N(C)C12)O)=O)=O)=O)=O)=O)=O)=O)C=O)=O 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VORHXBNOSKWXDL-UHFFFAOYSA-N NC(C(N)=O)=C(N)N Chemical compound NC(C(N)=O)=C(N)N VORHXBNOSKWXDL-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41327510P | 2010-11-12 | 2010-11-12 | |
| US61/413,275 | 2010-11-12 | ||
| PCT/US2011/060407 WO2012065085A1 (en) | 2010-11-12 | 2011-11-11 | Methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013542264A JP2013542264A (ja) | 2013-11-21 |
| JP2013542264A5 true JP2013542264A5 (cg-RX-API-DMAC10.html) | 2014-12-25 |
Family
ID=46048353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538937A Pending JP2013542263A (ja) | 2010-11-12 | 2011-11-11 | 癌を処置する方法 |
| JP2013538939A Pending JP2013542264A (ja) | 2010-11-12 | 2011-11-11 | 癌を処置する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538937A Pending JP2013542263A (ja) | 2010-11-12 | 2011-11-11 | 癌を処置する方法 |
Country Status (15)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| BRPI0812970A2 (pt) | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
| US8987281B2 (en) | 2010-11-12 | 2015-03-24 | Endocyte, Inc. | Methods of treating cancer |
| CN103607891A (zh) * | 2011-04-12 | 2014-02-26 | 恩多塞特公司 | 固体药用组合物 |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
| EP3574924B1 (en) | 2013-11-19 | 2021-01-06 | Purdue Research Foundation | Patient selection method for inflammation |
| PT3134123T (pt) | 2014-02-21 | 2021-03-22 | Nektar Therapeutics India Pvt Ltd | Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1 |
| CN103816548A (zh) * | 2014-03-11 | 2014-05-28 | 北京林业大学 | 靶向亲水性聚合物-雷公藤甲素结合物 |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| US20170035894A1 (en) * | 2014-04-14 | 2017-02-09 | Endocyte, Inc. | Drug delivery conjugates for treating resistant cancer and for use in combination therapy |
| CN112638363B (zh) * | 2018-08-31 | 2025-01-24 | 太阳医药工业有限公司 | 卡铂的肠胃外剂型 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6441026B1 (en) * | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
| KR20040106547A (ko) * | 2002-05-15 | 2004-12-17 | 엔도사이트, 인코포레이티드 | 비타민-마이토마이신 공액체 |
| US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| US7601332B2 (en) * | 2003-01-27 | 2009-10-13 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| CN101239190B (zh) * | 2003-01-27 | 2013-09-25 | 恩多塞特公司 | 维生素受体结合递药缀合物 |
| DE602006012816D1 (de) * | 2005-03-30 | 2010-04-22 | Endocyte Inc | Tifizierung von zellulären folat vitamin rezeptoren |
| JP2009504783A (ja) * | 2005-08-19 | 2009-02-05 | エンドサイト，インコーポレイテッド | ビンカアルカロイド、類似体および誘導体のリガンド結合体 |
| US20070065449A1 (en) * | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
| BRPI0812970A2 (pt) | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
| JP5675619B2 (ja) * | 2008-09-17 | 2015-02-25 | エンドサイト, インク.Endocyte, Inc. | 葉酸拮抗薬の葉酸受容体結合性コンジュゲート |
| EP2350320A4 (en) * | 2008-11-12 | 2012-11-14 | Caris Life Sciences Luxembourg Holdings | METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES |
| US20120128587A1 (en) * | 2009-07-31 | 2012-05-24 | Endocyte, Inc. | Folate-targeted diagnostics and treatment |
| US8987281B2 (en) | 2010-11-12 | 2015-03-24 | Endocyte, Inc. | Methods of treating cancer |
-
2011
- 2011-11-11 US US13/294,624 patent/US8987281B2/en not_active Expired - Fee Related
- 2011-11-11 AU AU2011325989A patent/AU2011325989C1/en not_active Ceased
- 2011-11-11 WO PCT/US2011/060407 patent/WO2012065085A1/en not_active Ceased
- 2011-11-11 EA EA201390694A patent/EA025069B1/ru not_active IP Right Cessation
- 2011-11-11 EP EP11840607.3A patent/EP2638397A4/en not_active Withdrawn
- 2011-11-11 CN CN2011800634321A patent/CN103282777A/zh active Pending
- 2011-11-11 EP EP11839397.4A patent/EP2638395A4/en not_active Withdrawn
- 2011-11-11 MX MX2013005194A patent/MX2013005194A/es unknown
- 2011-11-11 KR KR1020137013272A patent/KR20130140033A/ko not_active Ceased
- 2011-11-11 JP JP2013538937A patent/JP2013542263A/ja active Pending
- 2011-11-11 EA EA201390695A patent/EA026168B1/ru not_active IP Right Cessation
- 2011-11-11 SG SG2013036306A patent/SG190245A1/en unknown
- 2011-11-11 CN CN201180061415.4A patent/CN103403552B/zh not_active Expired - Fee Related
- 2011-11-11 AU AU2011325982A patent/AU2011325982C1/en not_active Ceased
- 2011-11-11 BR BR112013011590-4A patent/BR112013011590A2/pt not_active IP Right Cessation
- 2011-11-11 CA CA2817223A patent/CA2817223A1/en not_active Abandoned
- 2011-11-11 MX MX2013005196A patent/MX2013005196A/es unknown
- 2011-11-11 CA CA2817219A patent/CA2817219A1/en not_active Abandoned
- 2011-11-11 WO PCT/US2011/060395 patent/WO2012065079A1/en not_active Ceased
- 2011-11-11 JP JP2013538939A patent/JP2013542264A/ja active Pending
- 2011-11-11 SG SG2013036280A patent/SG190244A1/en unknown
- 2011-11-11 US US13/884,842 patent/US8883737B2/en not_active Expired - Fee Related
- 2011-11-11 KR KR1020137013270A patent/KR20130140032A/ko not_active Ceased
- 2011-11-11 BR BR112013011659A patent/BR112013011659A2/pt not_active IP Right Cessation
-
2013
- 2013-03-13 US US13/800,254 patent/US20140066383A1/en not_active Abandoned
- 2013-05-09 IL IL226246A patent/IL226246A0/en unknown
- 2013-05-09 IL IL226247A patent/IL226247A0/en unknown
- 2013-05-13 CL CL2013001322A patent/CL2013001322A1/es unknown
- 2013-05-13 CL CL2013001324A patent/CL2013001324A1/es unknown
- 2013-06-10 ZA ZA2013/04225A patent/ZA201304225B/en unknown
- 2013-06-10 ZA ZA2013/04226A patent/ZA201304226B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542263A5 (cg-RX-API-DMAC10.html) | ||
| JP2014525449A5 (cg-RX-API-DMAC10.html) | ||
| CN103945902B (zh) | 地西他滨衍生物制剂 | |
| US10485764B2 (en) | Lyophilized pharmaceutical compositions | |
| WO2007082978A1 (es) | Una formulación farmacéutica de taxano, una composición sólida de taxano, un procedimiento para la preparación de dicha composición sólida de taxano, una composición solubilizante de dicha composición sólida de taxano, y un conjunto de elementos (kit) par | |
| ES2414472T3 (es) | Composición farmacéutica de liberación sostenida de acetato de octreotide | |
| JP2019526596A5 (cg-RX-API-DMAC10.html) | ||
| JP6182262B2 (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
| RU2016141569A (ru) | Комбинации | |
| KR20170023088A (ko) | 정제된 치료용 나노입자 및 이의 제조방법 | |
| JP2015532295A5 (cg-RX-API-DMAC10.html) | ||
| JP2019515908A5 (cg-RX-API-DMAC10.html) | ||
| JP2015535243A5 (cg-RX-API-DMAC10.html) | ||
| CN111888329A (zh) | 注射剂 | |
| EP3197430A1 (en) | Long acting pharmaceutical compositions | |
| JP2013541587A (ja) | Ｎｅｄｄ８活性化酵素阻害剤の投与 | |
| CN101081219B (zh) | 一种含紫杉烷类化合物的组合物、其制备方法和用途 | |
| JP2017505313A5 (cg-RX-API-DMAC10.html) | ||
| Li et al. | Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer | |
| WO2007075452A2 (en) | Lyophilized compositions of a triazolopyrimidine compound | |
| CN104706599B (zh) | 一种携带膜海鞘素化合物的冻干粉针剂 | |
| RU2018114922A (ru) | Лечение очаговой алопеции | |
| JP4891912B2 (ja) | 非水性極性溶媒中の１０−ヒドロキシカンプトテシン化合物の溶解度を増加させるための薬剤製剤 | |
| WO2012029076A2 (en) | Stable pharmaceutical composition | |
| CN113018268B (zh) | 一种注射用德拉沙星葡甲胺冻干制剂及其制备方法 |